Coronavirus: US awards $1.6bn to Novavax for vaccine

Final testing phase for candidate planned for July

Powered by automated translation

The US on Tuesday announced it was providing $1.6 billion in funding for the development and manufacture of a Covid-19 vaccine candidate produced by biotech firm Novavax, the largest amount awarded under Operation Warp Speed.

Separately, the US said it was providing $450 million (Dh1.65 billion) to Regeneron for its experimental Covid-19 treatment and prophylaxis, a combination of two antibodies.

Under the terms of its agreement with the Department of Health and Human Services and Department of Defence, Novavax agrees to deliver 100 million doses of its vaccine, potentially by the end of the year.

“We are honoured to partner with Operation Warp Speed to move our vaccine candidate forward with extraordinary urgency in the quest to provide vital protection to our nation’s population,” said Stanley Erck, the company’s president and chief executive.

The final stage Phase 3 trial of its vaccine, called NVX-CoV2373, is due to take place this autumn.

The Maryland-based company uses insect cells to grow synthesised pieces of the “spike protein” the virus uses to invade cells and trigger an immune system response.

It also uses an adjuvant, a compound that boosts the production of neutralising antibodies.

In spring, the company said it had proven the efficacy of a seasonal flu vaccine it had developed using similar technology.

The amount awarded to Novavax by the US is higher than the $1.2 billion given to the Oxford University vaccine being developed by AstraZeneca.

Under Operation Warp Speed, the US aims to deliver millions of doses of safe and effective vaccines for Covid-19 in 2021.

Also on Tuesday, the US said it was giving Regeneron, based in New York State, $450 million to boost production of its Covid-19 antibody.

The company, which announced on Monday it was entering late-stage human trials, estimates that it could have between 70,000 and 300,000 treatment doses, with the first available by late summer.

The drug, called REGN-COV2, is a combination of two antibodies that block the coronavirus’s spike protein.

Regeneron scientists evaluated thousands of antibodies harvested from genetically modified mice with human immune systems and from humans, identifying the two they found to be most potent, while not competing against each other.

The company uses a multi-antibody strategy to decrease the chances that the virus will mutate to evade the blocking action of a single antibody, an approach it detailed in a recent study in Science.

Last year, a triple antibody cocktail developed by Regeneron was shown to be effective against the Ebola virus.